• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Dapagliflozin associated with reduced hospitalization rate for heart failure

byJames RoebkerandDayton McMillan
January 25, 2019
in Cardiology, Chronic Disease, Endocrinology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Among patients with type 2 diabetes and established or multiple risk factors for cardiovascular disease (CVD), dapagliflozin was noninferior but did not significantly reduce the rate of major adverse cardiovascular events (MACE) compared to placebo.

2. Dapagliflozin significantly reduced the hospitalization rates for heart failure compared to placebo in both patients with established CVD and those with only multiple risk factors.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Two sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin and canagliflozin, have been shown to decrease cardiovascular morbidity and mortality in type 2 diabetic patients at high risk for CVD. This reports the results of the DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58) trial, designed to evaluate the cardiovascular safety and efficacy of the SGLT2 inhibitor dapagliflozin. Over 17,000 patients with type 2 diabetes and established or multiple risk factors for CVD were randomized to dapagliflozin or placebo. The investigators found that dapagliflozin was noninferior but not superior compared to placebo with respect to the incidence of MACE (the primary outcome). Dapagliflozin significantly reduced the composite of cardiovascular death and hospitalization for heart failure; however, this was due to a significant reduction in hospitalizations for heart failure without a significant difference in cardiovascular death. This trial suggests dapagliflozin is has a safe cardiovascular profile in patients with type 2 diabetes, and also suggests that the heart failure benefit of SGLT2 inhibitors extends to the primary prevention population.

This was a large, randomized trial that added to the growing body of safety and efficacy data for the SGLT2 inhibitors. Another major strength was the large primary prevention population included in the study (nearly 60% of participants), which generalize the results to a broader range of type 2 diabetes patients. A limitation of this study includes the potential for higher medication compliance than seen in the general diabetic population, given the one-month trial run-in period.

Click to read the study in NEJM

Relevant Reading: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes

RELATED REPORTS

Dapagliflozin efficacious and safe in treating heart failure

Interatrial shunt device not effective in patients with symptomatic heart failure

#VisualAbstract: Effectiveness of sacubitril-valsartan in post-myocardial infarction management compared to ramipril

In-Depth [randomized controlled trial]: Patients (17,160) with established or multiple risk factors for CVD (40.7% with established CVD) were randomized to treatment with dapagliflozin (n=8,582) or a matching placebo (n=8,578). The primary safety outcome was incidence of MACE (defined as a composite of cardiovascular death, myocardial infarction, or ischemic stroke), and the two primary efficacy outcomes were MACE and a composite of cardiovascular death or hospitalization for heart failure. Prespecified secondary outcomes included a renal composite outcome (sustained decrease in estimated glomerular filtration rate [eGFR], new end-stage renal disease, or death from renal or cardiovascular causes) and death from any cause. Serious adverse events were collected throughout the trial period.

Median follow-up duration was 4.2 years. The average reduction in hemoglobin A1C with dapagliflozin was 0.42%. The primary outcome of MACE for dapagliflozin vs. placebo met the prespecified threshold for noninferiority (upper boundary of the 95% confidence interval [CI], <1.3; P<0.001), but not superiority (8.8% vs. 9.4%, respectively; hazard ratio [HR], 0.93; 95% CI, 0.84 to 1.03; P=0.17). There was a significant difference in the composite of cardiovascular death and hospitalization for heart failure (4.9% vs. 5.8%; P=0.005); however, this was due to a significantly lower rate of hospitalization for heart failure (2.5% vs. 3.3%; P<0.005) without a significant difference in cardiovascular death (2.9% vs. 2.9%; HR, 0.98; 95% CI, 0.82 to 1.17). Among secondary outcomes, there was a significant difference in composite renal outcome (4.3% vs. 5.6%; HR, 0.76; 95% CI, 0.67 to 0.87), and no significant difference in all-cause mortality (9.2% vs. 6.6%; HR, 0.93; 95% CI, 0.82 to 1.04). The results regarding cardiovascular death and hospitalization for heart failure were similar across subgroups (including established CVD and those with only risk factors). Among additional safety outcomes, the dapagliflozin group had a higher rate of diabetic ketoacidosis (0.3% vs. 0.1%; P=0.02) and genital infections (0.9% vs. 0.1%; P<0.001). There was no significant difference in the rate of amputations, stroke, or fractures between dapagliflozin and placebo.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: dapagliflozinheart failureMACE
Previous Post

The LEAP trial: levodopa not associated with a disease-modifying effect in Parkinson’s disease

Next Post

Quick Take: Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site

RelatedReports

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Dapagliflozin efficacious and safe in treating heart failure

May 13, 2022
30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Interatrial shunt device not effective in patients with symptomatic heart failure

March 29, 2022
StudyGraphics

#VisualAbstract: Effectiveness of sacubitril-valsartan in post-myocardial infarction management compared to ramipril

February 10, 2022
Cardiology

Sacubitril or valsartan versus standard medical therapies in patients with heart failure with preserved ejection fraction: PARALLAX trial

November 17, 2021
Next Post
Survivors of adult-onset cancers associated with increased incidence of cardiovascular disease

Quick Take: Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site

#VisualAbstract: Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis

#VisualAbstract: Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

Solitary kidney not associated with contrast-induced nephropathy

Quick Take: Neutrophil–Lymphocyte Ratio as a Predictor of Kidney Function Decline Among Diabetes and Pre-diabetes (a 3-year follow-up study)

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.